NCT07001995 2026-03-16
Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression
Hunan Province Tumor Hospital
Phase 2 Not yet recruiting
Clinical Trials
460 trialsNCT04919382 2026-03-12
Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
Big Ten Cancer Research Consortium
Phase 2 Recruiting
NCT07468656 2026-03-12
SCLC Tarlatamab Blood Collection
Duke University
Not yet recruiting
NCT04170946 2026-03-05
Talazoparib
University Health Network, Toronto
Phase 1 Recruiting
NCT04516070 2026-03-05
Stereotactic Radiosurgery for the Treatment of Patients With Small Cell Lung Cancer Brain Metastasis
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03223155 2026-03-04
COSINR
University of Chicago
Phase 1 Active not recruiting
NCT05068232 2026-03-04
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
University of Chicago
Phase 2 Recruiting
NCT07402343 2026-03-04
T-BRAIN
Maastricht University Medical Center
Phase 2 Not yet recruiting
NCT06719700 2026-03-03
Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer
Sun Yat-sen University
Phase 2 Recruiting
NCT07219251 2026-03-03
EVLC
Palo Alto Veterans Institute for Research
Phase NA Recruiting
NCT07434518 2026-02-25
A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Recruiting
NCT05403723 2026-02-19
Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC
University of Maryland, Baltimore
Phase 1 Suspended
NCT07149363 2026-02-17
Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
Alliance Foundation Trials, LLC.
Phase 2 Recruiting
NCT03830918 2026-02-12
Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy
Jonsson Comprehensive Cancer Center
Phase 1/2 Active not recruiting
NCT06730685 2026-02-12
PHILUCA
Zealand University Hospital
Enrolling by invitation
NCT07050472 2026-02-12
Durvalumab After Concurrent Chemoradiotherapy (cCRT) for Limited-stage Small-cell Lung Cancer (LS-SCLC)
Peking University Cancer Hospital & Institute
Completed
NCT05419076 2026-02-11
A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05703269 2026-02-10
HYPOGRYPHE
Wake Forest University Health Sciences
Phase NA Recruiting
NCT07398560 2026-02-10
Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer: An Exploratory Clinical Study
The Third Affiliated Hospital of Harbin Medical University
Phase 2 Not yet recruiting
NCT07390565 2026-02-09
YSQTG Combined With Immuno-chemotherapy for Extensive-Stage Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase NA Enrolling by invitation
NCT05620342 2026-02-05
Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer
UNC Lineberger Comprehensive Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT07388875 2026-02-05
SKB264-ANLO
China Medical University, China
Phase 2 Not yet recruiting
NCT05616624 2026-02-04
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers
Washington University School of Medicine
Phase 1/2 Active not recruiting
NCT07242547 2026-02-04
MERLIN
Fundación GECP
Phase 2 Recruiting
NCT07383454 2026-02-03
Lung Cancer Screening in Population Who Had Never Smoked
Chung Shan Medical University
Phase NA Not yet recruiting
NCT07339059 2026-01-30
SG and Immunotherapy as Maintenance Therapy for Extensive-stage Small-cell Lung Cancer
Henry Ford Health System
Phase 2 Recruiting
NCT07376499 2026-01-29
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
China Medical University, China
Phase 2 Not yet recruiting
NCT05223647 2026-01-28
TRIPLEX
Norwegian University of Science and Technology
Phase 3 Terminated
NCT07373964 2026-01-28
A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD-L1 Inhibitor, Carboplatin, and Etoposide as First-Line Treatment in Patients With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
China Medical University, China
Phase 2 Recruiting
NCT07057791 2026-01-27
PrE0510
PrECOG, LLC.
Phase 2 Recruiting
NCT07357532 2026-01-22
Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD
Peking University Cancer Hospital & Institute
Phase 2 Not yet recruiting
NCT06481813 2026-01-21
BREATHE
Nantes University Hospital
Phase NA Recruiting
NCT03467360 2026-01-20
ICAR
Centre Antoine Lacassagne
Phase 1 Recruiting
NCT06957314 2026-01-20
A Study of Hospital-at-Home for People Receiving Tarlatamab
Memorial Sloan Kettering Cancer Center
Phase NA Recruiting
NCT03923270 2026-01-08
Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Active not recruiting
NCT04199741 2026-01-07
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT00213798 2025-12-22
Detection of Plasma DNA in Non Small Cell and Small Cell Lung Cancer Patients
University Hospital, Strasbourg, France
Phase NA Completed
NCT07155200 2025-12-22
Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)
Washington University School of Medicine
Phase 1/2 Recruiting
NCT03728361 2025-12-18
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT07153055 2025-12-18
LOTS
Indiana University
Phase 1/2 Not yet recruiting
NCT05450965 2025-12-17
Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
University of Maryland, Baltimore
Phase 2 Recruiting
NCT04701307 2025-12-15
Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06758700 2025-12-05
Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Recruiting
NCT04010357 2025-12-02
Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC
Case Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT07243132 2025-11-25
LUNGEVITY
Groupe Francais De Pneumo-Cancerologie
Recruiting
NCT07249879 2025-11-25
This Study is an Open-lable, Phase I Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1 Not yet recruiting
NCT05588388 2025-11-17
BELIEVE
Cedars-Sinai Medical Center
Phase 2 Recruiting
NCT03672773 2025-11-10
TRIO-US L-07
Jonsson Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT04373369 2025-11-03
Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Washington University School of Medicine
Phase 2 Terminated
NCT05265429 2025-10-29
Biology of Young Lung Cancer Study: The YOUNG LUNG Study
Dana-Farber Cancer Institute
Recruiting